ArticleFrontiers in immunology2026
α7nAChR alleviates cognitive impairment by promoting autophagy in astrocytes via CaMKK2/AMPK/mTOR pathway in sepsis-associated encephalopathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated encephalopathy (SAE) is a syndrome of cerebral dysfunction secondary to sepsis. Although the α7 nicotinic acetylcholine receptor (α7nAChR) plays a pivotal role in the SAE, the specific mechanisms by which it mediates neuroinflammatory responses and contributes to pathological injury in SAE remain unclear. Methods: The serum α7nAChR level was measured in all included patients. The ROC curve was used to analyze the α7nAChR level for predicting the risk of SAE. The sepsis rat model was constructed by cecal ligation puncture (CLP). The α7nAChR was activated and inhibited by PNU282987 and Methyllycaconitine (MLA) respectively. Cognitive function and neuronal damage were evaluated using behavioral experiment, Nissl staining, Golgi staining and Electron microscopy. Autophagy was examined by Western blot (WB) and transmission electron microscope (TEM). Results: The serum α7nAChR levels in SAE patients were lower than that in the healthy controls and sepsis patients, and the its AUC for predicting the risk of SAE was 0.79 (95% CI, 0.68-0.90). Activation of the α7nAChR elevated neurobehavioral scores, increased the number of Nissl bodies and synapses, and improved dendritic spine morphology in rats. Activation of α7nAChR weakened the activation of astrocytes, thereby reducing the release of IL-1β, IL-6 and TNF-α. The activation of α7nAChR inhibited the level of P62, up-regulated the expression of LC3. Conclusion: α7nAChR can alleviate cognitive dysfunction in SAE by activating the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.